News

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study

13.04.2018 08:00

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study aimed at evaluating the activating effects of Lipiodol®-based conventional transarterial chemoembolization (cTACE) on the immunity of patients with hepatocellular carcinoma (HCC)

▪ HCC is the second leading cause of cancer mortality worldwide

▪ Evaluation of the immunogenic potential of cTACE

Villepinte (France), April 13, 2018 (8:00 am CEST) – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne’s University Hospital (CHUV) and the Lausanne Center for Experimental Therapies (CTE) to launch a study aimed at evaluating the activating effects of Lipiodol®-based conventional transarterial chemoembolization (cTACE) on the immunity of patients with hepatocellular carcinoma (HCC).

Hepatocellular carcinoma: the second leading cause of cancer-related death worldwide.

There are nearly 800,000 new cases of HCC each year worldwide. It is a primary liver cancer tumor that causes over 700,000 deaths annually throughout the world and has one of the highest incidence rates in Western countries. It is the most common form of primary liver cancer, and results generally from an underlying liver disease of various origins (hepatitis B or C, alcoholic cirrhosis, non-alcoholic steatohepatitis).

cTACE, a possible activator of the anti-tumor immune system

cTACE is the reference treatment for patients with intermediate-stage HCC and has been demonstrated to significantly improve patient survival compared to supportive palliative therapy. Nevertheless, and despite progress brought by new medical practices, there is an urgent need to develop new therapies to fight this pathology which has a poor prognosis.

Recent innovations include immunotherapy, aimed at stimulating or restoring the immune responses that specifically fight the tumor. It is an approach that has elicited much interest and is the subject of several clinical trials for HCC treatment. Modern cancer treatment of most types of tumor involves a combination of several therapies used either sequentially or simultaneously, with the aim of obtaining an additive and sometimes even synergistic therapeutic effect. Combining local treatments, such as cTACE, with systemic immunotherapy promises to improve the tolerance and individual effectiveness of treatments.

Study objectives and scope

In this context, local treatments like cTACE could play an essential role by activating and/or restoring the systemic and/or local immune system which fights patients’ liver tumors. Preliminary results1 confirm the potential of this technique in terms of “paving the way” for systemic immunotherapy. Additional data are needed to accurately identify the role of cTACE in inducing and/or reactivating an immune response and to determine the possible synergy between this treatment and immunotherapy.

The partners will work together to clarify the immunomodulatory and activating mechanisms induced by a cTACE procedure in 20 patients with HCC, by measuring variations in the expression of different families of genes and of proteins involved in the anti-tumor immune response.

The study, to be conducted on the premises of the CHUV, will be coordinated by Dr. Rafael Duran, principal investigator and member of the CHUV Department of Radiodiagnosis and Interventional Radiology, and Professor Lana Kandalaft, co-investigator and Director of the CTE, located within the Lausanne CHUV Oncology Department.

“Hepatocellular carcinoma is the second leading cause of cancer-related death worldwide. The innovative immunotherapy approach, which uses the immune system’s anti-tumor capacities, has delivered promising results and is opening up new treatment perspectives for an ever-increasing number of patients,” said Professor Alban Denys, Head of the CHUV Interventional Radiology Unit.

“It is essential that we improve our understanding and characterization of the anti-tumor effects of cTACE and that we study its ability to convert poorly immunogenic tumors, also called ‘immune deserts’, into immunogenic tumors. By reprogramming the tumor microenvironment, we could combine cTACE with immunotherapy,” added Dr. Rafael Duran from the CHUV Department of Radiodiagnosis and Interventional Radiology.

“We are delighted to announce the launch of this new study, the results of which will provide a solid foundation for explaining the role of cTACE as an activator of patients’ anti-tumor immune systems and pave the way for new combination therapeutic approaches, which represent the future of HCC management,” commented Dr. Pierre Desché, Development, Medical and Regulatory Affairs VP at Guerbet.

“We will be combining one of the best equipped technological platforms in the world with the knowledge of CTE’s scientists and doctors, creating a unique opportunity to identify the immune mechanisms involved at the molecular and cellular level after cTACE," said Professor Lana Kandalaft, Director of the Center of Experimental Therapeutics (CTE), CHUV.